FdaApplication
NDA 208081
Identifiers
- fda_app_no: NDA208081
Properties
| Property | Value |
|---|---|
| applicant_name | BIOFRONTERA INC |
| application_type | NDA |
| approval_date | 2016-05-10 |
Revenue by product
AMELUZ
| Period | Revenue |
|---|---|
| Q1 2025 | $150.0M |
| Q1 2024 | $150.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AMELUZ | AMINOLEVULINIC ACID HYDROCHLORIDE | 10% | GEL;TOPICAL |
1 product